Media stories about Affimed N.V. (NASDAQ:AFMD) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Affimed N.V. earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Affimed N.V. (NASDAQ:AFMD) traded down 2.27% on Tuesday, reaching $2.15. The company had a trading volume of 285,233 shares. Affimed N.V. has a 52-week low of $1.65 and a 52-week high of $3.23. The stock’s market capitalization is $94.47 million. The stock has a 50 day moving average price of $2.23 and a 200 day moving average price of $2.23.

Affimed N.V. (NASDAQ:AFMD) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.51 million during the quarter, compared to analysts’ expectations of $1.31 million. Affimed N.V. had a negative net margin of 978.31% and a negative return on equity of 73.85%. Affimed N.V.’s revenue for the quarter was down 75.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.24) EPS. Analysts expect that Affimed N.V. will post ($0.84) EPS for the current year.

A number of research firms have recently weighed in on AFMD. SunTrust Banks, Inc. began coverage on Affimed N.V. in a research report on Thursday, July 13th. They issued a “buy” rating and a $7.00 price objective for the company. Oppenheimer Holdings, Inc. set a $10.00 price target on Affimed N.V. and gave the stock a “buy” rating in a research report on Saturday, April 15th. Zacks Investment Research cut Affimed N.V. from a “buy” rating to a “hold” rating in a report on Friday, April 21st. ValuEngine upgraded Affimed N.V. from a “strong sell” rating to a “sell” rating in a research note on Friday, June 30th. Finally, Jefferies Group LLC lifted their price target on Affimed N.V. to $2.50 and gave the company a “hold” rating in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $4.80.

WARNING: “Affimed N.V. (NASDAQ:AFMD) Earning Somewhat Favorable Media Coverage, Report Finds” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/08/affimed-n-v-nasdaqafmd-earning-somewhat-favorable-press-coverage-study-shows-updated-updated-updated.html.

Affimed N.V. Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Insider Buying and Selling by Quarter for Affimed N.V. (NASDAQ:AFMD)

Receive News & Stock Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related stocks with our FREE daily email newsletter.